StanleyRabanFrankelMD

PubMed

• 46 citations
  The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
  Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo, Kathryn J. Newhall, Angus M. Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B. Walter> ;Plos One. 2015 Aug 25
• 132 citations
  Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
  George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary Means, Angus M. Sinclair, Roman Kischel, Stanley R Frankel,...> ;Blood. 2014 Jan 23
• 46 citations
  Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid recepto...
  Reinhard Dummer, Marc Beyer, Kenneth B. Hymes, Mirjam T. Epping, René Bernards, Matthias Steinhoff, Wolfram Sterry, Helmut Kerl, Karl Heath, Janet D. Ahern, James S. H...> ;Leukemia & Lymphoma. 2012 Jan 12
• 113 citations
  High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)
  Yixuan Gong, Evelyn Yao, Ronglai Shen, Aviva Goel, Maria E. Arcila, Julie Teruya-Feldstein, Maureen F. Zakowski, Stanley R. Frankel, Martin Peifer, Roman K. Thomas, Ma...> ;Plos One. 2009 Oct 6
• Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).
  Gong Y, Yao E, Arcila M, Frankel S, Teruya-Feldstein J, Zakowski M, Thomas R, Ladanyi M, Pao W> ;J. Clin. Oncol.. 2009-05-20
• 213 citations
  Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized P...
  Howard S. Hochster, Edie Weller, Randy D. Gascoyne, Thomas M. Habermann, Leo I. Gordon, Theresa Ryan, Lijun Zhang, Natalia Colocci, Stanley Frankel, Sandra J. Horning> ;Journal of Clinical Oncology. 2009 Apr 1
• 120 citations
  Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
  Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R...> ;Blood. 2008 Nov 16
• 135 citations
  Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
  Valeria R. Fantin, Andrey Loboda, Cloud P. Paweletz, Ronald C. Hendrickson, Jacqueline W. Pierce, Jennifer A. Roth, Lixia Li, Frank Gooden, Susan Korenchuk, Xiaoli S. ...> ;Cancer Research. 2008 May 15
• 148 citations
  Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
  Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, L. Sun, Justin L. Ricker, H. Xie, Stanley R. Frankel, Sophia Randolph, Bruce D. Cheson> ;Annals of Oncology. 2008 May 1
• 137 citations
  Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and ...
  George R. Blumenschein, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Charles Lu, Ashok Kumar, Justin L. Ricker, Judy Chiao, Cong Chen, Stanley R. Frankel> ;Investigational New Drugs. 2008 Feb 1
• 458 citations
  Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
  Guillermo Garcia-Manero, H. Yang, Carlos E. Bueso-Ramos, Alessandra Ferrajoli, Jorge E. Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary L. ...> ;Blood. 2008 Feb 1
• 747 citations
  Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
  Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker, Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduin...> ;Journal of Clinical Oncology. 2007 Jul 20
• 826 citations
  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
  Madeleine Duvic, Rakhshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R...> ;Blood. 2007 Jan 1
• 94 citations
  A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
  Eric H. Rubin, Nancy G. B. Agrawal, Evan J. Friedman, Pamela Scott, Kathryn E. Mazina, L. Sun, Lihong Du, Justin L. Ricker, Stanley R. Frankel, Keith Gottesdiener, Joh...> ;Clinical Cancer Research. 2006 Dec 1
• Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial.
  Olsen E, Kim YH, Kuzel T, Pacheco TR, Foss F, Parker S, Wang JG, Frankel SR, Lis J, Duvic M> ;J. Clin. Oncol.. 2006-06-20
• 35 citations
  The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide
  Owen A. O'Connor, Emily A. Smith, Lorraine E. Toner, Julie Teruya-Feldstein, Stanley R. Frankel, Mark Rolfe, Xiaohui Wei, Shujun Liu, Guido Marcucci, Kenneth K. Chan, ...> ;Clinical Cancer Research. 2006 May 1
• 15 citations
  Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first rem...
  Martin S. Tallman, Waleska S. Pérez, Hillard M. Lazarus, Robert Peter Gale, Richard T. Maziarz, Jacob M. Rowe, David I. Marks, Jean-Yves Cahn, Asad Bashey, Michael R. ...> ;Biology of Blood and Marrow Transplantation. 2006 Feb 1
• 330 citations
  Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematol...
  Owen A. O'Connor, Mark L. Heaney, Lawrence H. Schwartz, Stacie Richardson, Robert D. Willim, Barbara MacGregor-Cortelli, Tracey Curly, Craig H. Moskowitz, Carol S. Por...> ;Journal of Clinical Oncology. 2006 Jan 1
• 143 citations
  Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
  Meir Wetzler, Ben L. Sanford, Joanne Kurtzberg, Divino Deoliveira, Stanley R. Frankel, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Richard A. Larson> ;Blood. 2005 Nov 16
• 176 citations
  Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patient...
  Eric J. Feldman, Joseph Brandwein, Richard Stone, Matt Kalaycio, Joseph O. Moore, Julie O'Connor, Nancy Wedel, Gail J. Roboz, Carole B. Miller, Rajesh Chopra, Joseph C...> ;Journal of Clinical Oncology. 2005 Jun 20
• Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab.
  Colocci N, Weller E, Hochster HS, Gascoyne R, Kumm B, Ryan T, Habermann TM, Frankel SR, Horning SJ> ;J. Clin. Oncol.. 2005-06-01
• Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy.
  Duvic M, Talpur R, Zhang C, Goy A, Richon V, Frankel SR> ;J. Clin. Oncol.. 2005-06-01
• 116 citations
  A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
  Anthony W. Tolcher, Kim N. Chi, John G. Kuhn, Martin E. Gleave, Amita Patnaik, Chris H. Takimoto, Garry Schwartz, Ian M. Thompson, K. Berg, Susan D’Aloisio, Nevin Murr...> ;Clinical Cancer Research. 2005 May 15
• 145 citations
  Extended rituximab therapy in Waldenström's macroglobulinemia
  Steven P. Treon, Christos Emmanouilides, Eva Kimby, Abigail S. Kelliher, Frederic I. Preffer, Andrew R. Branagan, Kenneth C. Anderson, Stanley R. Frankel> ;Annals of Oncology. 2005 Jan 1
• Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.
  Treon SP, Hansen M, Branagan A, Emmanouilides C, Kimby E, Frankel S, Touroutoglou N, Maloney D, Anderson KC, Fox EA> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all